Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease.

Tuttle KR, Meyerhoff J, Sun Z, Shah SV, Rossing P, Wang B

DOI: 10.1177/27558428251411738
Published: 2026 Jan-Dec
Container: Sage open chronic disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/27558428251411738,
  title = {Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease.},
  author = {Tuttle KR and Meyerhoff J and Sun Z and Shah SV and Rossing P and Wang B},
  year = {2026},
  journal = {Sage open chronic disease},
  doi = {10.1177/27558428251411738},
  url = {https://doi.org/10.1177/27558428251411738}
}

RIS

TY  - JOUR
TI  - Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease.
AU  - Tuttle KR
AU  - Meyerhoff J
AU  - Sun Z
AU  - Shah SV
AU  - Rossing P
AU  - Wang B
PY  - 2026
JO  - Sage open chronic disease
DO  - 10.1177/27558428251411738
UR  - https://doi.org/10.1177/27558428251411738
ER  -

APA

KR, T., J, M., Z, S., SV, S., P, R., & B, W. (2026). Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease.. Sage open chronic disease. https://doi.org/10.1177/27558428251411738

Source records

pubmed · retrieved 2026-09-26T12:09:16.476Z